title: Percutaneous coronary implantation of sirolimus-eluting stents in unselected patients and lesions: clinical results and multiple outcome predictors.
abstract: BACKGROUND
  Sirolimus-eluting stents (SES) prevent restenosis and repeat percutaneous coronary intervention (PCI), but safety data in unselected patients are limited, especially for intermediate-term follow-up.
  
  
  METHODS
  All patients undergoing SES implantation at 4 Italian centers were enrolled into a dedicated database. Baseline, procedural, and outcome data at discharge and at follow-up were abstracted. Outcomes of interest were the occurrence of major adverse cerebrocardiovascular events (MACCE) at 6 months, as well as long-term event-free survival and multivariable event predictors.
  
  
  RESULTS
  One thousand four hundred twenty-four patients were enrolled (2,915 lesions, treated with 3,305 stents). Specifically, 1,074 (75.4%) subjects had multivessel disease, 399 (28.1%) had diabetes, 89 (6.3%) had ST-elevation myocardial infarction, and 44 (3.1%) underwent unprotected left main intervention. At 6 months, MACCE had occurred in 121 (9.0%) patients. After a median of 48.7 months (first-third quartile 41.8-55.3), MACCE-free survival was 69.2%+/-2.6%, with definite stent thrombosis occurring acutely in 6 (0.4%), subacutely in 11 (0.8%), after 30 days in 12 (0.8%), and cumulatively in 28 (2.0%). Major multivariable outcome predictors were diabetes (target lesion revascularization [TLR], MACCE), ejection fraction (TLR, MACCE), and maximal balloon length (TLR).
  
  
  CONCLUSIONS
  This large cohort of unselected patients supports the overall safety of unrestricted percutaneous SES implantation, as shown by the low rates of stent thrombosis. Event attrition remains, however, high at long-term follow-up, driven mainly by target vessel revascularization, with diabetes and ejection fraction as the most important prognostic factors.
authors.affiliation: Interventional Cardiology Unit, St Raffaele Hospital, Milan, Italy. sangiorgi@emocolumbus.it
authors.forename: Giuseppe
authors.initials: G
authors.lastname: Sangiorgi
authors.forename: Enrico
authors.initials: E
authors.lastname: Romagnoli
authors.forename: Giuseppe
authors.initials: G
authors.lastname: Biondi-Zoccai
authors.forename: Massimo
authors.initials: M
authors.lastname: Margheri
authors.forename: Corrado
authors.initials: C
authors.lastname: Tamburino
authors.forename: Rossella
authors.initials: R
authors.lastname: Barbagallo
authors.forename: Elena
authors.initials: E
authors.lastname: Falchetti
authors.forename: Guido
authors.initials: G
authors.lastname: Vittori
authors.forename: Pierfrancesco
authors.initials: P
authors.lastname: Agostoni
authors.forename: John
authors.initials: J
authors.lastname: Cosgrave
authors.forename: Antonio
authors.initials: A
authors.lastname: Colombo
mesh_terms: D003327:Coronary Disease / Q000628:therapy*; D054855:Drug-Eluting Stents / Q000009:adverse effects; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D011379:Prognosis; D019919:Prosthesis Implantation / Q000009:adverse effects / Q000379:methods*; D012189:Retrospective Studies; D020123:Sirolimus / Q000008:administration & dosage*
chemical_list: D020123:Sirolimus